Evidence map›Paper›PMID 33664931›Full record

ReviewThe World Allergy Organization journal2020

Oral immunotherapy for peanut allergy: The con argument.

Alessandro Fiocchi, Maria Cristina Artesani, Vincenzo Fierro, Carla Riccardi, Lamia Dahdah, Maurizio Mennini

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The World Allergy Organization journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alessandro FiocchiAllergy Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Maria Cristina ArtesaniAllergy Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Vincenzo FierroAllergy Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Carla RiccardiAllergy Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Lamia DahdahAllergy Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Maurizio MenniniAllergy Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Bambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn some countries of the world, peanut allergy represents an important source of anaphylactic reactions. Traditionally treated with the avoidance of responsible allergens, this condition can also be targeted by oral peanut immunotherapy.

methodsIn this study, we review the beneficial and side effects of currently available forms of peanut oral immunotherapy (POIT). We report the discussions resulting from the publication of a meta-analysis that brought to light the downsides of oral immunotherapy for peanuts.

resultsIn some clinical situations, the risk-benefit ratio can favor peanut oral immunotherapy over avoidance. In many other situations, this is not the case. The decision must be based on the values and preferences of clinicians and patients. Those not ready to accept serious adverse effects from POIT are likely to continue the elimination diet; those motivated to achieving desensitization, and prepared to accept serious adverse effects, may choose to undergo POIT.

conclusionsWithout being prejudiced against peanut oral immunotherapy, we indicate the possible evolution of treatment for this condition is in a rapidly evolving broader scenario. Among the future options, sublingual immunotherapy, parenteral immunotherapy with modified allergens, transcutaneous immunotherapy, and the use of biologics will become important options.

Indexed as

EAACI, European academy of allergy asthma and immunologyEfficacyICER, Institute for clinical and economic reviewOFC, Oral food challengeOIT, Oral ImmunoTherapyOral immunotherapyOUtMATCH, Omalizumab as monotherapy and as adjunct therapy to multi-allergen OIT in Food allergic participantsPACE, Peanut allergen immunotherapy, clarifying the evidence meta-analysisPeanut allergyPOISED, Peanut oral immunotherapy Study:Safety, efficacy and discoveryPOIT, Peanut oral ImmunoTherapyQoL, Quality of lifeQuality of lifeSafetySCIT, Subcutaneous immunotherapySLIT, Sublingual immunotherapySPT, Skin prick test

Identifiers

PMID33664931
PMCPMC7897709
OpenAlexW3088570790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.